Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

Item
http://www.wikidata.org/entity/Q37438970
Pazopanib in the treatment of advanced renal cell carcinomaMultimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapyPlatelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment.Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale"Thyroid dysfunctions induced by tyrosine kinase inhibitors.Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma.Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma.Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors:Survival outcomes of double- and triple-sequential targeted therapy in patients with metastatic renal cell carcinoma: a retrospective comparison.Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
P2860

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

Item
http://www.wikidata.org/entity/Q37438970
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Outcomes of patients with meta ...... with other targeted therapies
@en
Outcomes of patients with meta ...... with other targeted therapies.
@nl
type
label
Outcomes of patients with meta ...... with other targeted therapies
@en
Outcomes of patients with meta ...... with other targeted therapies.
@nl
prefLabel
Outcomes of patients with meta ...... with other targeted therapies
@en
Outcomes of patients with meta ...... with other targeted therapies.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P932
P356
P1433
P1476
Outcomes of patients with meta ...... with other targeted therapies
@en
P2093
P2860
P304
P31
P356
10.1016/J.EJCA.2013.06.003
P433
P478
P577
P698
P932